Phaseline

Targets › AR

AR (Androgen receptor): drug programs, companies and trials

66 programs from 60 companies in 247 trials: 138 Phase 2, 61 Phase 3, 33 Phase 1, 15 Phase 4; Oncology, Metabolic and endocrine, Genitourinary; next expected readout Nov 2026.

Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling…. (UniProt, P10275)

Open in Phaseline: the race on AR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ottawa Hospital Research InstituteARPI (androgen receptor pathway inhibitor)
Androgen receptor pathway inhibitor
ARPhase 4Metastatic Breast CancerMar 2027
BayerDarolutamide
Androgen Receptor antagonist
ARPhase 4Non-metastatic Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Cancer; Cancer; High-risk Localized Prostate Cancer …Jul 2027
Bradley NindlTestosterone
Androgen Receptor agonist
ARPhase 4Musculoskeletal InjuryAug 2027
Alexandra Kautzky-WillerTestosterone
Androgen Receptor agonist
ARPhase 4Fatty LiverSep 2028
Lise AksglædeTestosterone
Androgen Receptor agonist
ARPhase 4Klinefelter SyndromeDec 2029
Sun Pharmaceutical IndustriesClascoterone
Androgen Receptor antagonist
ARPhase 4Acne Vulgaris–
TolmarTestosterone Undecanoate
Androgen Receptor agonist
ARPhase 4Hypogonadism; Prostate Cancer–
Johnson & Johnson (Janssen)Apalutamide
Androgen Receptor antagonist
ARPhase 3Prostatic Neoplasms; Metastatic Castrate-sensitive Prostate CancerDec 2026
Université de SherbrookeAndrogen blockade (18 months) + radiation therapy
LHRH agonist with initial total androgen blockade for 18 months combined with pelvic and p
ARPhase 3Prostate CancerDec 2026
Aragon PharmaceuticalsApalutamide (ARN-509)
Androgen Receptor antagonist
ARPhase 3Prostatic Neoplasms; Prostate Cancer; Prostatic Neoplasms, Castration-Resistant; Androgen Axis Suppression …Mar 2027
Jiangsu HengRui MedicineRezvilutamide
Androgen Receptor antagonist
ARPhase 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer (Post Prostatectomy) …Mar 2027
Amneal PharmaceuticalsTestosterone Cypionate
Androgen Receptor agonist
ARPhase 3Male Hypogonadism; Weaning Failure; Transgenderism; Localized Prostate Carcinoma …Mar 2027
Khyber Medical University PeshawarDanazol
Progesterone receptor agonist; Androgen Receptor agonist
PGR, ARPhase 3Beta-ThalassemiaApr 2027
University of Sao Paulo General HospitalTestosterone
Androgen Receptor agonist
ARPhase 3MenopauseApr 2027
PfizerEnzalutamide
Androgen Receptor antagonist
ARPhase 3Hormone Sensitive Prostate CancerJul 2027
Merck & Co. (MSD)Opevesostat (MK-5684)
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor blocking steroid hormone synt
HSD11B1, ARPhase 3Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer Metastatic; Malignant Neoplasm; Prostatic Neoplasms, Castration-Resistant …Nov 2027
Canisius-Wilhelmina HospitalTestosterone
Androgen Receptor agonist
ARPhase 3Prostatic NeoplasmsDec 2027
Halozyme TherapeuticsTestosterone Enanthate
Androgen Receptor agonist
ARPhase 3Hypogonadism, Male; Spinal Cord Injury; Prostate Cancer; Castration Resistant Metastatic Prostate Cancer …Mar 2028
NovartisEnzalutamide
Androgen Receptor antagonist
ARPhase 3Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms; Castration-Resistant Prostate Carcinoma …Sep 2028
Sir Mortimer B. Davis - Jewish General HospitalTestosterone
Androgen Receptor agonist
ARPhase 3Prostate CancerDec 2028
AstellasEnzalutamide
Androgen Receptor antagonist
ARPhase 3Metastatic Hormone Sensitive Prostate CancerDec 2028
Assistance Publique - Hôpitaux de ParisTestosterone
Androgen Receptor agonist
ARPhase 3Gender DysphoriaJun 2029
Radiation Therapy Oncology GroupAnti-androgen
Androgen receptor antagonist
ARPhase 3Prostate CancerJul 2031
Canadian Cancer Trials GroupTestosterone
Androgen Receptor agonist
ARPhase 3Prostate CancerOct 2032
Sun Yat-sen UniversityTestosterone
Androgen Receptor agonist
ARPhase 3Prostate Cancer (Post Prostatectomy)Dec 2033
European Organisation for Research and Treatment of Cancer - EORTCiMAB (intermittent maximum androgen blockade)
Intermittent LHRH agonist/antagonist + ARPI (abiraterone, enzalutamide, apalutamide, or da
ARPhase 3Prostate CancerMay 2035
Zhejiang Sunshine Mandi PharmaceuticalClascoterone
Androgen Receptor antagonist
ARPhase 3Acne Vulgaris; Papular-pustular Rosacea; Pilonidal Disease–
Seattle Institute for Biomedical and Clinical ResearchTestosterone
Androgen Receptor agonist
ARPhase 2Hypogonadism, MaleNov 2026
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairAbiraterone
Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor
CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3Phase 2Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma …Nov 2026
Martin T. King, MD, PhDAndrogen Deprivation Therapy (ADT)
Lowering testosterone levels to slow or shrink prostate tumors; may include injectable or
ARPhase 2Intermediate Risk Prostate CancerDec 2026
University of Wisconsin, MadisonpTVG-AR
DNA vaccine encoding androgen receptor ligand-binding domain
ARPhase 2Castration-resistant Prostate Cancer; Prostate CancerDec 2026
Fudan UniversitySHR 3680
Androgen receptor antagonist
ARPhase 2Advanced Salivary Gland CarcinomaDec 2026
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolDarotamide
Androgen receptor antagonist
ARPhase 2Neoadjuvant TherapyDec 2026
University Hospital, GhentTestosterone
Androgen Receptor agonist
ARPhase 2Prostate CancerDec 2026
University of Maryland, Baltimoregaleterone
Androgen Receptor antagonist; Cytochrome P450 17A1 inhibitor
AR, CYP17A1Phase 2Advanced Pancreatic CancerDec 2026
University Hospital, Clermont-FerrandTestosterone
Androgen Receptor agonist
ARPhase 2Critical IllnessApr 2027
Science Valley Research InstituteOxandrolone
Androgen Receptor agonist
ARPhase 2Anterior Cruciate Ligament (ACL) ReconstructionApr 2027
University of Southern CaliforniaDanazol
Progesterone receptor agonist; Androgen Receptor agonist
PGR, ARPhase 2Cirrhosis, LiverAug 2027
VA Office of Research and DevelopmentTestosterone
Androgen Receptor agonist
ARPhase 2Metastatic Prostate CancerAug 2027
VeruEnobosarm
Androgen Receptor modulator
ARPhase 2Obesity & OverweightOct 2027
University Hospital, Strasbourg, FranceTestosterone
Androgen Receptor agonist
ARPhase 2Multiple Sclerosis, Relapsing-RemittingDec 2027
Sun Pharmaceutical IndustriesEnzalutamide
Androgen Receptor antagonist
ARPhase 2Metastatic CancerDec 2027
University of VirginiaTestosterone
Androgen Receptor agonist
ARPhase 2Prostate CancerJan 2028
RocheEnzalutamide
Androgen Receptor antagonist
ARPhase 2Metastatic Castration-Resistant Prostate CancerMar 2028
St. Louis UniversityTestosterone
Androgen Receptor agonist
ARPhase 2Hypogonadism, MaleJun 2028
University of WashingtonTestosterone
Androgen Receptor agonist
ARPhase 2Castration-Resistant Prostate CarcinomaSep 2028
QuantumLeap Healthcare CollaborativeTestosterone
Androgen Receptor agonist
ARPhase 2Ductal Carcinoma in SituNov 2028
Case Comprehensive Cancer CenterTestosterone
Androgen Receptor agonist
ARPhase 2Prostate CancerDec 2028
University of ChicagoTestosterone
Androgen Receptor agonist
ARPhase 2Prostate CancerDec 2028
VA Office of Research and DevelopmentFlutamide
Androgen Receptor antagonist
ARPhase 2Prostate CancerMar 2029
Astellasenzalutamide
Androgen Receptor antagonist
ARPhase 2Prostate CancerJul 2029
Memorial Sloan Kettering Cancer CenterBMS986365 (CC-94676)
Androgen receptor (AR) ligand-directed degrader
ARPhase 2Prostate CancerJan 2030
City of Hope Medical CenterADT (Androgen Deprivation Therapy)
Androgen receptor pathway inhibition through hormone depletion
ARPhase 2Prostate CancerMay 2030
University of Texas Southwestern Medical CenterTestosterone
Androgen Receptor agonist
ARPhase 2Prostate CancerNov 2030
Affidea Nu-med Center of Oncological DIagnostics and TherapyTestosterone
Androgen Receptor agonist
ARPhase 2Prostate Cancer; Prostate Cancer (Adenocarcinoma)Dec 2033
AstraZenecaAZD9750
AR-PROTAC (proteolysis-targeting chimera)
ARPhase 1Prostate CancerNov 2026
Qilu PharmaceuticalQLH12016
Androgen receptor PROTAC
ARPhase 1Advanced Prostate CancerDec 2026
Johnson & Johnson (Janssen)JNJ-86974680
ARv7 inhibitor
ARPhase 1Prostatic NeoplasmsJan 2027
Alessa TherapeuticsBicalutamide
Androgen Receptor antagonist
ARPhase 1Prostate Adenocarcinoma; Androgen Deprivation Therapy; Prostate Cancer; Castration Levels of Testosterone …Apr 2027
NovartisARV-766
Androgen receptor antagonist
ARPhase 1Prostate Cancer MetastaticMay 2027
University of California, Los AngelesTestosterone
Androgen Receptor agonist
ARPhase 1Hypogonadism, MaleJun 2027
Weill Medical College of Cornell UniversityTestosterone
Androgen Receptor agonist
ARPhase 1Prostate CancerOct 2027
Hansoh BioMedical R&D CompanyHRS-5041
Androgen receptor PROTAC degrader
ARPhase 1Advanced Prostate CancerDec 2027
St Vincent's Hospital, SydneySeviteronel
Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist
CYP17A1, ARPhase 1Triple Negative Breast CancerDec 2027
Ellipses PharmaEP0062
Selective androgen receptor modulator (SARM)
ARPhase 1Hormone Receptor-positive Breast CancerFeb 2028
Alessa TherapeuticsEnzalutamide
Androgen Receptor antagonist
ARPhase 1Prostate AdenocarcinomaDec 2028

Conditions

Prostate Cancer (74) Prostatic Neoplasms (11) Prostate Adenocarcinoma (9) Metastatic Castration-resistant Prostate Cancer (8) Metastatic Prostate Cancer (7) Castration-Resistant Prostate Carcinoma (7) Hypogonadism, Male (5) Prostatic Neoplasms, Castration-Resistant (4) Prostate Cancer Metastatic Disease (4) Prostate Cancer Metastatic (3) Prostate Cancer (Adenocarcinoma) (3) Neoadjuvant Therapy (3)

Modalities

small molecule (58), mixed (5), antibody (1)

Companies

Johnson & Johnson (Janssen) (2) Novartis (2) Astellas (2) VA Office of Research and Development (2) Alessa Therapeutics (2) Sun Pharmaceutical Industries (2) Martin T. King, MD, PhD (1) Hansoh BioMedical R&D Company (1) Merck & Co. (MSD) (1) University of California, Los Angeles (1) QuantumLeap Healthcare Collaborative (1) Bayer (1) Qilu Pharmaceutical (1) Lise Aksglæde (1) University Hospital, Strasbourg, France (1) Canisius-Wilhelmina Hospital (1) Aragon Pharmaceuticals (1) Alexandra Kautzky-Willer (1) Weill Medical College of Cornell University (1) Affidea Nu-med Center of Oncological DIagnostics and Therapy (1)

Related targets

CYP17A1 (3) PGR (2) HSD11B1 (1) SRD5A1 (1) SRD5A2 (1) SRD5A3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.